Skip to main content

Diffuse Scleroderma clinical trials at UCSD
1 in progress, 0 open to eligible people

  • Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis

    Sorry, in progress, not accepting new patients

    This is a Phase 3 multicenter, double-blind, randomized, placebo-controlled study assessing the efficacy and safety of lenabasum for the treatment of diffuse cutaneous systemic sclerosis (SSc). Approximately 354 subjects will be enrolled in this study at about 60 sites in North America, Europe, Australia, and Asia. The planned duration of treatment with study drug is 52 weeks.

    La Jolla, California and other locations

Last updated: